ESC 2025: Real-World Data Demonstrates Effectiveness of Semaglutide in Swiss Patients with Type 2 Diabetes

Study Findings: A study presented at the European Society of Cardiology’s 2025 Congress showed that oral semaglutide significantly reduced HbA1c and body weight in adults with type 2 diabetes in Switzerland, with 90.8% of participants completing the study and 77.3% remaining on treatment at the end of the study period.

Market Implications: The positive results and high patient compliance with oral semaglutide are expected to increase its prescribing rates, enhancing Novo Nordisk's position in the GLP-1 market amidst growing competition.